Patient Knowledge, Beliefs and Barriers to Hepatitis B Care: Results of a Multicenter, Multiethnic Patient Survey.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
02 2021
Historique:
received: 27 11 2019
accepted: 18 03 2020
pubmed: 3 4 2020
medline: 29 4 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

A greater understanding of the determinants of health behavior among those with and at-risk of chronic hepatitis B virus (HBV) infection is needed for effective design and implementation of public health initiatives. To determine factors associated with (1) willingness to accept HBV antiviral treatment and (2) satisfaction with provider communication regarding HBV care in a diverse cohort of HBV-infected patients. Using a multifaceted model of health behavior, the Health Behavior Framework, we conducted a comprehensive assessment of knowledge, attitudes, beliefs, and barriers to HBV care. We enrolled 510 patients, with mean age 46 years; 53.1% men; and 71.6% Asian or Hawaiian/Pacific Islander. Patients were knowledgeable about HBV infection, but one-fifth did not think that HBV was a treatable disease; over a quarter felt it was so common among family and friends that it did not concern them, and less than half of patients believed they were likely to have liver problems or transmit HBV to others during their lifetime. Perceived susceptibility to disease risk was the only independent predictor of willingness to accept HBV treatment (β = 0.23, p = 0.0005), and contrary to expectations, having a doctor that speaks the same language was predictive of lower patient satisfaction with provider communication about their HBV care (β = - 0.65, p < 0.0001). Patients with greater perceived susceptibility to the health consequences of HBV infection are more likely to accept treatment, and patient-provider language concordance impacts patient satisfaction with communication regarding HBV care in an unexpected direction.

Sections du résumé

BACKGROUND
A greater understanding of the determinants of health behavior among those with and at-risk of chronic hepatitis B virus (HBV) infection is needed for effective design and implementation of public health initiatives.
AIMS
To determine factors associated with (1) willingness to accept HBV antiviral treatment and (2) satisfaction with provider communication regarding HBV care in a diverse cohort of HBV-infected patients.
METHODS
Using a multifaceted model of health behavior, the Health Behavior Framework, we conducted a comprehensive assessment of knowledge, attitudes, beliefs, and barriers to HBV care.
RESULTS
We enrolled 510 patients, with mean age 46 years; 53.1% men; and 71.6% Asian or Hawaiian/Pacific Islander. Patients were knowledgeable about HBV infection, but one-fifth did not think that HBV was a treatable disease; over a quarter felt it was so common among family and friends that it did not concern them, and less than half of patients believed they were likely to have liver problems or transmit HBV to others during their lifetime. Perceived susceptibility to disease risk was the only independent predictor of willingness to accept HBV treatment (β = 0.23, p = 0.0005), and contrary to expectations, having a doctor that speaks the same language was predictive of lower patient satisfaction with provider communication about their HBV care (β = - 0.65, p < 0.0001).
CONCLUSIONS
Patients with greater perceived susceptibility to the health consequences of HBV infection are more likely to accept treatment, and patient-provider language concordance impacts patient satisfaction with communication regarding HBV care in an unexpected direction.

Identifiants

pubmed: 32239377
doi: 10.1007/s10620-020-06224-3
pii: 10.1007/s10620-020-06224-3
pmc: PMC7529692
mid: NIHMS1581141
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

434-441

Subventions

Organisme : NIAAA NIH HHS
ID : K24 AA022523
Pays : United States
Organisme : Gilead Sciences
ID : IX-US-174-0204

Références

BMC Public Health. 2017 Sep 26;17(1):747
pubmed: 28950835
J Gastroenterol Hepatol. 2010 Feb;25(2):369-75
pubmed: 19929923
Int J Environ Res Public Health. 2018 Dec 24;16(1):
pubmed: 30586847
Am J Health Behav. 2017 Sep 1;41(5):561-570
pubmed: 28760178
Can J Public Health. 2003 Jul-Aug;94(4):281-6
pubmed: 12873087
J Gen Intern Med. 2015 Jan;30(1):68-74
pubmed: 25324148
Clin Gastroenterol Hepatol. 2015 Jan;13(1):183-92
pubmed: 25010003
Curr Opin Psychol. 2015 Oct 1;5:85-89
pubmed: 26258160
Dig Dis Sci. 2011 May;56(5):1516-23
pubmed: 21046247
Prev Med. 2010 Jan-Feb;50(1-2):63-7
pubmed: 19716379
J Gen Intern Med. 2018 Apr;33(4):404-405
pubmed: 29404941
J Clin Gastroenterol. 2017 Aug;51(7):626-631
pubmed: 27811627
MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20
pubmed: 18802412
Dig Dis Sci. 2014 Jan;59(1):46-56
pubmed: 24052195
Hepatology. 2015 Nov;62(5):1339-41
pubmed: 26239816
Prev Chronic Dis. 2014 May 01;11:E72
pubmed: 24784908
Ann Fam Med. 2004 Nov-Dec;2(6):595-608
pubmed: 15576546
J Gen Intern Med. 2007 Nov;22 Suppl 2:324-30
pubmed: 17957419
Prev Med. 2004 Feb;38(2):209-18
pubmed: 14715214
Asia Pac J Oncol Nurs. 2016 Oct-Dec;3(4):324-334
pubmed: 28083549
J Viral Hepat. 2011 Jun;18(6):377-83
pubmed: 21143343
Prev Med. 2010 Jan-Feb;50(1-2):68-73
pubmed: 19883680
J Gen Intern Med. 2008 Jun;23(6):808-15
pubmed: 18415653

Auteurs

Nizar A Mukhtar (NA)

Department of Gastroenterology, Kaiser Permanente San Francisco Medical Center, 2350 Geary Blvd., 2nd Floor, San Francisco, CA, 94115, USA.

Donna M Evon (DM)

Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, 8010 Burnett-Womack Building, 101 Manning Drive, Chapel Hill, NC, 27599, USA.

Colina Yim (C)

Toronto Centre for Liver Disease, University Health Network, University of Toronto, 585 University Ave., Norman Urquhart Building, 13th Floor, Toronto, ON, M5G 2N2, USA.

Anna S Lok (AS)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA.

Nadra Lisha (N)

Department of Medicine, University of California San Francisco, 530 Parnassus Ave., Rm 363, San Francisco, CA, 94143, USA.

Mauricio Lisker-Melman (M)

Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8124, St. Louis, MO, 63110, USA.

Mohamed Hassan (M)

Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, 420 Delaware Street SE, MMC 36, Minneapolis, MN, 55455, USA.

Harry L A Janssen (HLA)

Toronto Centre for Liver Disease, University Health Network, University of Toronto, 585 University Ave., Norman Urquhart Building, 13th Floor, Toronto, ON, M5G 2N2, USA.

Mandana Khalili (M)

Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, Zuckerberg San Francisco General Hospital, 1001 Potrero Ave., Building 5, Suite 3D, Ward 3D-4, San Francisco, CA, 94110, USA. mandana.khalili@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH